| Autor: |
Oyake T; Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Japan., Maeta T; Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Japan., Takahata T; Department of Gastroenterology, Hematology and Clinical Immunology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan., Tamai Y; Department of Transfusion and Cell Therapy Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan., Kameoka Y; Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan., Takahashi N; Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan., Miyairi Y; Division of Hematology, Iwate Prefectural Central Hospital, Morioka, Japan., Murai K; Division of Hematology, Iwate Prefectural Central Hospital, Morioka, Japan., Shimosegawa K; Division of Hematology, Iwate Prefectural Chubu Hospital, Kitakami, Japan., Yoshida K; Division of Hematology, Iwate Prefectural Isawa Hospital, Oshu, Japan., Inokura K; Department of Hematology, Tohoku University Graduate School of Medicine, Sendai, Japan., Fukuhara N; Department of Hematology, Tohoku University Graduate School of Medicine, Sendai, Japan., Harigae H; Department of Hematology, Tohoku University Graduate School of Medicine, Sendai, Japan., Sato R; Division of Hematology and Cell Therapy, Department of Third Internal Medicine, Yamagata University Faculty of Medicine, Yamagata, Japan., Ishizawa K; Division of Hematology and Cell Therapy, Department of Third Internal Medicine, Yamagata University Faculty of Medicine, Yamagata, Japan., Tajima K; Department of Hematology, Yamagata Prefectural Central Hospital, Yamagata, Japan., Saitou S; Division of Hematology, Nihonkai General Hospital, Sakata, Japan., Fukatsu M; Department of Hematology, Fukushima Medical University, Fukushima, Japan., Ikezoe T; Department of Hematology, Fukushima Medical University, Fukushima, Japan., Tsunoda S; Department of Hematology, Aizu Medical Center Fukushima Medical University, Aizuwakamatsu, Japan., Mita M; Second Department of Internal Medicine, Shirakawa Kosei General Hospital, Shirakawa, Japan., Mori J; Department of Hematology, Joban Hospital, Tokiwa Foundation, Iwaki, Japan., Kowata S; Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Japan., Ito S; Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Japan. |
| Abstrakt: |
Immune checkpoint inhibitors (ICI) are promising therapeutic agents for relapsed or refractory classical Hodgkin's lymphoma (RRcHL). This retrospective study evaluated patients with RRcHL registered in the clinical research program Tohoku-Hematology-Forum-26, between 2016 and 2020, and treated with ICI in 14 centers in Northeast Japan. We analyzed the usage, efficacy, and safety of ICI therapy (ICIT). Among a total of 27 patients with RRcHL, 21 and nine were treated with nivolumab and/or pembrolizumab, respectively. The best response was complete response (CR), partial response (PR), stable disease (SD), and progressive disease in 11 (40.8%), seven (25.9%), eight (29.6%), and one (3.7%) patient, respectively. In all patients undergoing ICIT, the 2-year progression-free survival and 2-year overall survival (OS) were 48.6% and 87.4%, respectively. The 2-year OS for patients with CR, PR, and SD were 100%, 68.6%, and 87.5%, respectively. A total of 36 events of immune-related adverse events (irAEs) or immune-related like adverse events (irlAEs) were observed in 19 of the 27 patients (70.4%). Two thirds of these irAEs or irlAEs were grade 1-2 and controllable. During the observation period, ICIT was discontinued in 22 of 27 (81.4%) patients due to CR, inadequate response, irAE and patient circumstances in five (22.7%), seven (31.8%), eight (36.4%) and two patients (9.1%), respectively. Therapy-related mortality-associated irAE were observed in only one patient during ICIT. These results suggest that ICIT for RRcHL is effective and safe in real-world settings. The optimal timing of induction and duration of ICIT remains to be established. |
